leadf
logo-loader
viewOpen Orphan PLC

Open Orphan's Cathal Friel hails £4mln contract with top-three global pharma firm

Open Orphan PLC's (LON:ORPH) Cathal Friel tells Proactive its subsidiary hVIVO has signed a £4mln contract to conduct a human challenge study for an unnamed top-three global pharma company. The trial will take place at hVIVO’s London quarantine unit and is expected to be completed by the end of the first quarter next year.

Quick facts: Open Orphan PLC

Price: 17.125 GBX

AIM:ORPH
Market: AIM
Market Cap: £113.99 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Open Orphan PLC named herein, including the promotion by the Company of Open Orphan PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Open Orphan PLC: Proactive One2One Virtual Conference

Open Orphan PLC's (LON:ORPH) Cathal Friel presents at the Proactive One2One Virtual Conference. The company's a rapidly growing specialist CRO pharmaceutical services company which is a world leader in the testing of vaccines and antivirals through the use of human challenge clinical trials. It...

3 weeks, 6 days ago

2 min read